ROSETTA GENOMICS LTD. AND U.S. GENOMICS INC. ANNOUNCE COLLABORATION AGREEMENT

Rosetta Genomics Ltd. and U.S. Genomics Inc. announced today the signing of a discovery and co-development agreement for a microRNA-based, non-invasive early detection test for lung cancer. This collaboration combines U.S. Genomics' patented Trilogy 2020 platform and Direct miRNA assay with Rosetta Genomics' proprietary microRNAs. By using Rosetta Genomics' newly discovered microRNAs as biomarkers, together with U.S. Genomics' patented technology for sensitive molecular-level detection and quantitation, the two companies are working to create a new molecular diagnostic test to accurately identify lung cancer using a sputum or blood sample.
PR Newswire